Gain Therapeutics, Inc.
GANX
$2.12
-$0.05-2.08%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 10.59M | 10.07M | 8.95M | 8.72M | 10.40M |
| Gross Profit | -10.59M | -10.07M | -8.95M | -8.72M | -10.40M |
| SG&A Expenses | 9.12M | 8.66M | 8.65M | 8.54M | 9.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.71M | 18.73M | 17.59M | 17.26M | 20.35M |
| Operating Income | -19.71M | -18.73M | -17.59M | -17.26M | -20.35M |
| Income Before Tax | -20.30M | -19.30M | -18.10M | -17.84M | -20.31M |
| Income Tax Expenses | 943.70K | 861.10K | 1.30M | 757.40K | 617.40K |
| Earnings from Continuing Operations | -21.24 | -20.16 | -19.39 | -18.59 | -20.93 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.24M | -20.16M | -19.39M | -18.59M | -20.93M |
| EBIT | -19.71M | -18.73M | -17.59M | -17.26M | -20.35M |
| EBITDA | -19.67M | -18.69M | -17.55M | -17.22M | -20.31M |
| EPS Basic | -0.60 | -0.62 | -0.64 | -0.65 | -0.89 |
| Normalized Basic EPS | -0.36 | -0.37 | -0.37 | -0.39 | -0.54 |
| EPS Diluted | -0.60 | -0.62 | -0.64 | -0.65 | -0.89 |
| Normalized Diluted EPS | -0.36 | -0.37 | -0.37 | -0.39 | -0.54 |
| Average Basic Shares Outstanding | 145.39M | 131.84M | 121.73M | 113.26M | 102.14M |
| Average Diluted Shares Outstanding | 145.39M | 131.84M | 121.73M | 113.26M | 102.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |